半剂量替罗非班联合急诊介入治疗对急性冠脉综合征患者的疗效及安全性研究

目的通过对急性冠脉综合征（ACS）急诊介入治疗（PCI）患者使用不同剂量替罗非班的对比分析,探讨其临床疗效及安全性。方法对143例急性冠脉综合征行急诊PCI治疗患者进行分组,分为半剂量用药组（71例）和全剂量用药组（72例）两组。两组常规给予冠心病标准化治疗并替罗非班均以10μg/kg的负荷量在3min内静脉推注,随后全剂量用药组及半剂量用药组分别以0.15μg/（kg·min）和0.075μg/（kg·min）持续静脉泵入48h。比较两组患者血小板计数、肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）幅度、住院期间主要不良心血管事件（MACE）发生率、安全性指标。结果两组患者临床相关情况差异无统计学意义,两组患者术后IRA前向血流达到TIMⅠ3级的比例、CK幅度、CK-MB幅度、左心室射血分数（LVEF）、住院期间MACE比较差异无统计学意义。结论替罗非班对急性冠脉综合征接受PCI的患者是安全的,使用半剂量不增加心血管事件的发生率。

Efficacy and Safety of Half dose Tirofiban in Patients with Acute Coronary Syndrome Undergoing PCI

Objective To investigate the values and safety of tirofiban in different dose in patients with acute coronary syndrome （ACS）undergoing percutaneous coronary intervention （PCI）.Methods Totally 143 patients suffered from acute coronary syndromes were selected and divided into two groups according to dose （full dose and half dose）of tirofiban.Patients in two groups were given routinely standardized treatment of coronary heart disease and loading dose tirofiban 10μg/kg in 3 min.Then 0.15μg/（kg·min）and 0.075μg/（kg·min）were intravenously infused in 48 h in full dose group and half dose groups,respectively.Based clinical charac-teristics and TIMI blood flow grade after PCI,left ventricular ej ection fraction （LVEF）,the level of isoenzyme of creatine kinase MB （CK MB）,and major adverse cardiac events rates （MACE）during hospital after PCI were analyzed.Results There was no statisti-cal significance in the clinical data between the two groups.There was no statistical significance in the rate of IRA achieved TIMI3 af-ter operation,the level of CK MB,heart function,and early MACE between two groups.Conclusion Tirofiban was a safe and tolera-ble drug for ACS patients undergoing PCI.The half dose of it did not increase he incidence rate of cardiovascular events.